Congenital Myopathy Gene Panel in UAE | 4,800 AED | DHA Licensed

Executive Summary & Core Metrics

✓

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189 & ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).

🏥

Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.

📋

Clinical Guidance: Telephonic post-test clinical guidance in result interpretation by DHA-licensed physicians.

💰

Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731. Pre-approval support available.

Test Overview & Methodology

The Congenital Myopathy Gene Panel is a high-resolution Genetic Test that provides a definitive molecular diagnosis for conditions such as central core disease, nemaline myopathy, and centronuclear myopathy, enabling tailored management and genetic counseling.

Feature	Our Gene Panel (Gold Standard)	Closest Alternative (Single-Gene Tests)
Methodology	NGS with Copy Number Variant (CNV) analysis and full exon coverage	Sanger sequencing (one gene at a time)
Genes Covered	Over 35 core congenital myopathy genes (ACTA1, RYR1, NEB, MTM1, DNM2, etc.)	1 gene per analysis, missing 90% of possible mutations
Turnaround Time	4–6 weeks (expedited reporting for critical neonates)	6–12 weeks per gene, extremely delayed
Sample Types	Amniotic Fluid, Chorionic Villi, Peripheral Blood (versatile – hospital extraction only)	Peripheral Blood only
Clinical Utility	Differential diagnosis, family screening, prenatal use	Confirmatory only for known familial mutation

Physician Insight & Safety Protocols

"As a clinical geneticist, I always interpret this gene panel in the context of the full clinical picture—muscle biopsy, EMG, and family history. A negative result does not rule out disease, and a variant of uncertain significance requires careful correlation. This panel significantly shortens the diagnostic odyssey and empowers families with a clear genetic roadmap for early intervention."

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

⚠️ Medication and Clinical Warning

Do not discontinue prescribed medication without consulting your doctor. A gene panel result should never be used as the sole basis for adjusting muscle relaxants, antiepileptics, or immunosuppressants. Always discuss findings with the ordering physician.

Exclusion Criteria & Emergency Red Flags

Prenatal testing via amniotic fluid or chorionic villi requires written informed consent and genetic counseling documentation as per Federal Decree-Law No. 4 of 2016 on Medical Liability.
Minors (under 18 years) must have legal guardian consent per UAE PDPL and DHA guidelines; no testing without valid Emirates ID and signed authorization.
If the patient develops acute respiratory distress, severe hypotonia with swallowing difficulties, or malignant hyperthermia signs during sample collection, immediately call emergency services (998 for UAE) and defer elective genetic testing.
Sample collection is postponed if the patient has active fever over 38°C, uncontrolled seizures, or any acute decompensation that could compromise safety.

Patient FAQ & Clinical Guidance

1. What makes this Congenital Myopathy Gene Panel superior to a single‑gene test for my child’s muscle weakness?

This NGS panel simultaneously analyzes over 35 genes in a single run, delivering a definitive molecular diagnosis in 4–6 weeks. It avoids the prolonged, serial testing that delays critical early interventions and provides comprehensive coverage of known congenital myopathy genes.

2. Can the panel be performed during pregnancy, and what samples are required?

Yes, prenatal diagnosis is available using amniotic fluid (amniocentesis) or chorionic villi (CVS). Both sample types require prior genetic counseling and are processed under strict cold‑chain integrity. All prenatal collections are performed exclusively in hospital settings.

3. How does UAE PDPL protect my genetic data, and is my result kept confidential?

All genetic data is encrypted, stored within UAE sovereign cloud servers, and handled strictly under the UAE Personal Data Protection Law (PDPL) and DHA health information security standards, ensuring zero unauthorized access and full confidentiality.

UAE Regulatory & Data Privacy Adherence

Federal Decree‑Law No. 45 of 2021 (PDPL): All personal and genetic data is processed lawfully, with explicit consent, and stored exclusively on UAE‑based servers.

Federal Law No. 2 of 2019: Use of ICT in health fields—data integrity, cybersecurity, and patient privacy are fully enforced.

DHA Facility License 1143: Operations comply with Dubai Health Authority standards for genetic testing and laboratory accreditation.

Clinical & Logistical Metadata

Test Name	Congenital Myopathy Gene Panel
Price (AED)	4,800 AED
Turnaround Time	4–6 weeks (expedited if clinically indicated)
Sample Type / Matrix	Hospital Extraction Only – Amniotic Fluid, Chorionic Villi, Peripheral Blood (postnatal)
Methodology Used	Next‑Generation Sequencing (NGS) with CNV analysis, full exon coverage
ICD-10-CM Code	G71.2
LOINC Code	88826-7
DHA Facility License & Laboratory Address	License 1143 – DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE